

PROFESSIONAL INFORMATION FOR**CORYX COUGH AND COLD****SCHEDULING STATUS:****S2****1 NAME OF THE MEDICINE****CORYX COUGH AND COLD** 5 mL/10 mg/30 mg/1,25 mg solution.**2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 5 mL contains:	Dextromethorphan hydrobromide	10,0 mg
	Pseudoephedrine hydrochloride	30,00 mg
	Tripolidine hydrochloride	1,25 mg
	Alcohol 96 %	0,5 mL
Preservatives:	Propyl hydroxybenzoate	0,02 % m/v
	Methyl hydroxybenzoate	0,12 % m/v
Contains sugar:	Liquid Glucose	1,50 g
	Sucrose	1,00 g
	Sorbitol 70 %	2,40 g
Contains sweetener:	Saccharine sodium	7,50 mg

Other ingredients include citric acid, colourants [raspberry red (colour index number 14720)], menthol, purified water, sodium citrate, and strawberry flavour D421.

For full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

CORYX COUGH AND COLD is a clear red syrup with strawberry flavour.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

CORYX COUGH AND COLD is indicated for the alleviation of cough.

4.2 Posology and method of administration

Adults and children over 12 years: 10 ml

Children 6 to 12 years: 5 ml

Children 2 to 5 years: 2,5 ml

CORYX COUGH AND COLD should be given three times daily.

The dosage must not be exceeded.

CORYX COUGH AND COLD is contra-indicated in infants younger than 2 years of age (see **4.3 Contraindications**).

4.3 Contraindications

CORYX COUGH AND COLD is contraindicated in patients:

- With hypersensitivity to any of the ingredients.
- Younger than 2 years of age.

- With cardiovascular disease (especially coronary insufficiency).
- With hypertension.
- With prostatism.
- With thyrotoxicosis.
- With bladder dysfunction.
- With narrow angle glaucoma.
- With phaeochromocytoma.
- Being treated with monoamine oxidase inhibitors and within two weeks of stopping such treatment (see **4.5 Interaction with other medicines and other forms of interaction**).
- Being treated with ephedrine and other sympathomimetic agents, as a hypertensive response may result (see **4.5 Interaction with other medicines and other forms of interaction**).
- Who are pregnant or breast feeding as the safety has not been established (see **4.6 Fertility, pregnancy and lactation**).
- With asthma during an asthma attack.
- At risk of developing respiratory failure.

4.4 Special warnings and precautions for use

CORYX COUGH AND COLD may lead to drowsiness and impaired concentration, which may be aggravated by simultaneous intake of alcohol or other central nervous system depressant agents (see **4.7 Effects on ability to drive and use machines**).

It is possible that some sedating antihistamines, such as triprolidine, and therefore **CORYX COUGH AND COLD**, could mask the warning signs of ototoxic damage caused by medicines, such as aminoglycoside antibiotics.

Contains sucrose. Patients with rare hereditary conditions such as fructose intolerance, glucose-galactose mal-absorption or sucrase isomaltase insufficiency should not take **CORYX COUGH AND COLD**.

Contains glucose and sucrose which may have an effect on the glycaemic control of patients with diabetes mellitus.

Contains sorbitol and may have a laxative effect. Patients with the rare hereditary condition of sorbitol/ maltitol/ lactitol intolerance should not take **CORYX COUGH AND COLD**.

Pseudoephedrine, and therefore **CORYX COUGH AND COLD**, should be given with caution to patients with organic heart disease, cardiac decompensation or angina of effort and in patients receiving digoxin.

CORYX COUGH AND COLD should be used with caution in patients with diabetes mellitus, and with occlusive vascular disorders (arteriosclerosis).

Use carefully in elderly and debilitated patients. Elderly patients are more susceptible to the central nervous system depressant and hypnotic effects.

CORYX COUGH AND COLD should be used with caution in patients with cardiovascular disease, glaucoma, liver impairment, prostatic hypertrophy and urinary retention.

Antitussive agents should not be administered to patients with productive coughs. Dextromethorphan, and therefore **CORYX COUGH AND COLD**, should not be given to patients in, or at risk of, developing respiratory failure (see **4.3 Contraindications**).

Dextromethorphan abuse and dependence may occur, especially following prolonged use of high doses of **CORYX COUGH AND COLD**.

4.5 Interaction with other medicines and other forms of interaction

Triprolidine, and therefore **CORYX COUGH AND COLD**, may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.

Triprolidine, and therefore **CORYX COUGH AND COLD**, may have an additive antimuscarinic action when combined with other antimuscarinic medicines, such as atropine and some antidepressants (both tricyclic antidepressants and monoamine oxidase inhibitors).

It is possible that some sedating antihistamines, such as triprolidine, and therefore **CORYX COUGH AND COLD**, could mask the warning signs of ototoxic damage caused by medicines, such as aminoglycoside antibiotics.

Since antihistamines may suppress the cutaneous histamine response to allergen extracts, **CORYX COUGH AND COLD** should be discontinued several days before skin testing.

Triprolidine, and therefore **CORYX COUGH AND COLD**, may affect the metabolism of certain medicines in the liver.

Pseudoephedrine, and therefore **CORYX COUGH AND COLD**, may give rise to a hypertensive crisis in patients receiving monoamine oxidase inhibitors (MAOIs) [including reversible inhibitors of monoamine oxidase A (RIMAs)]. In addition there have been reports of severe and sometimes fatal reactions following the use of dextromethorphan in patients receiving MAOIs (see **4.3 Contraindications**).

Due to a possible interaction with pseudoephedrine, caution should be exercised when **CORYX COUGH AND COLD** is administered to patients undergoing anaesthesia with halothane or other halogenated anaesthetics.

There is an increased risk of dysrhythmias in patients receiving cardiac glycosides (digoxin), quinidine, or tricyclic antidepressants, as well as an increased risk of vasoconstrictor or pressor effects in patients receiving ergot alkaloids or oxytocin.

CORYX COUGH AND COLD should not be co-administered with quinidine or tricyclic antidepressants.

The effects of pseudoephedrine are diminished by guanethidine, reserpine and probably methyldopa and may be diminished or enhanced by antidepressants. Pseudoephedrine, and therefore **CORYX COUGH AND COLD**, may also diminish the effects of guanethidine and may increase the possibility of dysrhythmias in digitalised patients.

Concomitant use of **CORYX COUGH AND COLD** with sympathomimetic agents, such as nasal decongestants, appetite suppressants and amphetamine-like psychostimulants, or with medicines that interfere with the catabolism of sympathomimetic agents, may cause a rise in blood pressure largely because of interaction with pseudoephedrine (see **4.3 Contraindications**).

Because of its pseudoephedrine content, **CORYX COUGH AND COLD** may partially reverse the hypotensive action of medicines which interfere with sympathetic activity including bretylium, bethanidine, debrisoquine, methyldopa and beta-adrenergic blocking agents.

Since dextromethorphan is primarily metabolised by the cytochrome P450 isoenzyme CYP2D6, the possibility of interactions with inhibitors of this enzyme, including amiodarone, fluoxetine, haloperidol, paroxetine, propafenone, quinidine, and thioridazine, should be borne in mind when these medicines are co-administered with **CORYX COUGH AND COLD**.

4.6 Fertility, pregnancy and lactation

Pregnancy

The use of **CORYX COUGH AND COLD** is contraindicated during pregnancy and lactation (see **4.3 Contraindications**).

Breastfeeding

The use of **CORYX COUGH AND COLD** is contraindicated during pregnancy and lactation (see **4.3 Contraindications**).

4.7 Effects on ability to drive and use machines

CORYX COUGH AND COLD may lead to drowsiness and impaired concentration, which may be aggravated by simultaneous intake of alcohol or other central nervous system depressant agents. Patients should not drive, climb dangerous heights or operate machinery as impaired decision-making could lead to accidents.

4.8 Undesirable effects

Sedation or insomnia may occur.

Triprolidine as contained in CORYX COUGH AND COLD:

Blood and lymphatic system disorders:

Less frequent: Blood dyscrasias, including agranulocytosis, leucopenia, haemolytic anaemia, and thrombocytopenia.

Immune system disorders:

The following side-effects have been reported and frequencies are unknown:

Allergy, anaphylaxis, and hypersensitivity reactions (including bronchospasm and angioedema).

Metabolism and nutrition disorders:

The following side-effects have been reported and frequencies are unknown:

Sweating.

Psychiatric disorders:

Frequent: Sedation varying from slight drowsiness to deep sleep, and including lassitude, dizziness, and incoordination, although paradoxical stimulation may occasionally occur, especially at high doses

and in children or the elderly. Symptoms of cerebral stimulation in adults include insomnia, nervousness, tachycardia, tremors, muscle twitching, and convulsions.

The following side-effects have been reported and frequencies are unknown:

Inability to concentrate, elation or depression, irritability, nightmares, and sleep disturbances.

Nervous system disorders:

Frequent: Headache, and psychomotor impairment.

The following side-effects have been reported and frequencies are unknown:

Paraesthesia, tremor, muscular weakness, confusion, deepening coma, extrapyramidal effects, as well as tingling, heaviness, and weakness of the hands. Large doses may precipitate fits in epileptics.

Eye disorders:

Frequent: Blurred vision.

Ear and labyrinth disorders:

The following side-effects have been reported and frequencies are unknown:

Tinnitus.

Cardiac disorders:

The following side-effects have been reported and frequencies are unknown:

Hypotension, palpitations, dysrhythmias.

Respiratory, thoracic and mediastinal disorders:

Frequent: Thickened respiratory tract secretions.

The following side-effects have been reported and frequencies are unknown:

Tightness of the chest.

Gastrointestinal disorders:

Frequent: Dryness of the mouth, constipation, and increased gastric reflux.

The following side-effects have been reported and frequencies are unknown:

Nausea, vomiting, diarrhoea, colic, epigastric pain, and anorexia.

Skin and subcutaneous tissue disorders:

The following side-effects have been reported and frequencies are unknown:

Dermatological reactions may occur, including photosensitisation of the skin and lichenoid skin eruption; hair loss.

Musculoskeletal, connective tissue and bone disorders:

The following side-effects have been reported and frequencies are unknown:

Myalgia.

Renal and urinary disorders:

Frequent: Urinary difficulty or retention.

Pseudoephedrine as contained in CORYX COUGH AND COLD:**Endocrine disorders:**

The following side-effects have been reported and frequencies are unknown:

Disturbances of glucose metabolism.

Metabolism and nutrition disorders:

Less frequent: Sweating.

The following side-effects have been reported and frequencies are unknown:

Thirst.

Psychiatric disorders:

Frequent: Anxiety, restlessness, insomnia, and nervousness.

Less frequent: Hallucinations.

The following side-effects have been reported and frequencies are unknown:

Giddiness, agitation, fear, irritability, and psychotic states.

Nervous system disorders:

Less frequent: Convulsions, dizziness, headache, weakness and tremors.

The following side-effects have been reported and frequencies are unknown:

Confusion, fainting, and muscular weakness.

Eye disorders:

The following side-effects have been reported and frequencies are unknown:

Miosis.

Cardiac disorders:

Frequent: Tachycardia.

Less frequent: Reflex bradycardia, palpitations.

The following side-effects have been reported and frequencies are unknown:

Precordial pain, hypertension resulting in intracranial haemorrhage, anginal pain, especially in patients suffering from angina pectoris, cardiac dysrhythmias, cardiac arrest, flushing, vasoconstriction which may result in hypertension, and cerebral haemorrhage.

Respiratory, thoracic and mediastinal disorders:

Less frequent: Dyspnoea (shortness of breath) or troubled breathing.

The following side-effects have been reported and frequencies are unknown:

Pulmonary oedema.

Gastrointestinal disorders:

Less frequent: Nausea or vomiting.

The following side-effects have been reported and frequencies are unknown:

Loss of appetite, dry mouth.

Skin and subcutaneous tissue disorders:

Less frequent: Skin rashes.

The following side-effects have been reported and frequencies are unknown:

Fixed drug eruption due to pseudoephedrine, taking the form of erythematous nummular patches, have been reported.

Renal and urinary disorders:

Less frequent: Urinary retention, difficulty with micturition, especially in patients with prostatic enlargement, or painful urination.

General disorders:

Less frequent: Pallor.

Dextromethorphan as contained in CORYX COUGH AND COLD:**Psychiatric disorders:**

Less frequent: Drowsiness.

The following side-effects have been reported and frequencies are unknown:

Excitation. Toxic psychosis (hyperactivity, visual and auditory hallucinations) may occur.

Nervous system disorders:

Less frequent: Mental confusion, headache, and dizziness.

Respiratory, thoracic and mediastinal disorders:

The following side-effects have been reported and frequencies are unknown:

Respiratory depression may occur with very high doses.

Gastrointestinal disorders:

Less frequent: Constipation, nausea, vomiting, stomach pain, and gastrointestinal disturbance.

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the “**6.04 Adverse Drug Reactions Reporting Form**”, found online under SAHPRA’s publications: <https://www.sahpra.org.za/Publications/Index/8>

4.9 Overdose

The symptoms may include drowsiness, weakness, incoordination, difficulty with micturition, respiratory depression, irritability, convulsions, hypertension, palpitations and gastrointestinal disturbance.

Triprolidine intoxication may lead to ataxia, death from respiratory failure, and respiratory collapse. Overdosage may be fatal, especially in infants and children in whom main symptoms are central nervous system stimulation and antimuscarinic effects including ataxia, excitement, hallucinations, muscle tremor, convulsions, dilated pupils, dry mouth, flushed face and hyperpyrexia.

Respiratory depression can be treated with naloxone.

Treatment is symptomatic and supportive.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

A 10.1 Antitussives and expectorants.

Triprolidine hydrochloride is a sedating antihistamine with antimuscarinic and mild sedative effects.

Pseudoephedrine is a direct- and indirect-acting sympathomimetic with pressor activity and stimulant effects.

Dextromethorphan hydrobromide is a cough suppressant with a central action on the cough centre in the medulla.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Alcohol 96 %
- Citric acid
- Colourant – Raspberry red (Colour index number 14720)
- Liquid glucose
- Menthol
- Methyl hydroxybenzoate
- Propyl hydroxybenzoate
- Purified water
- Saccharine sodium
- Sodium citrate
- Sorbitol 70 %
- Sucrose

- Strawberry flavour D421.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store at or below 25 °C. Protect from light.

KEEP OUT OF REACH OF CHILDREN.

6.5 Nature and contents of the container

Amber glass bottles containing 100 mL.

7 HOLDER OF CERTIFICATE OF REGISTRATION

CIPLA MEDPRO (PTY) LTD.

Building 9, Parc du Cap

Mispel Street, Bellville

7530

8 REGISTRATION NUMBER

27/10.1/0490

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

19 July 1993

10 DATE OF REVISION OF THE TEXT

29 August 2021